Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey. more
Time Frame | OTLK | Sector | S&P500 |
---|---|---|---|
1-Week Return | -10.56% | -3.39% | 0.2% |
1-Month Return | -72.07% | -1.92% | 2.72% |
3-Month Return | -76.16% | -10.54% | 7.31% |
6-Month Return | -80.95% | -4.47% | 10.44% |
1-Year Return | -80.9% | 4.06% | 27.53% |
3-Year Return | -95.03% | 0.94% | 30.88% |
5-Year Return | -93.85% | 36.67% | 89.21% |
10-Year Return | -99.79% | 102.87% | 199.95% |
Sep '19 | Sep '20 | Sep '21 | Sep '22 | Sep '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 8.15M | 5.85M | - | - | - | [{"date":"2019-09-30","value":100,"profit":true},{"date":"2020-09-30","value":71.86,"profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true}] |
Cost of Revenue | 23.80K | 554.07K | 262.14K | 204.69K | 44.19K | [{"date":"2019-09-30","value":4.3,"profit":true},{"date":"2020-09-30","value":100,"profit":true},{"date":"2021-09-30","value":47.31,"profit":true},{"date":"2022-09-30","value":36.94,"profit":true},{"date":"2023-09-30","value":7.98,"profit":true}] |
Gross Profit | 8.12M | (554.07K) | (262.14K) | (204.69K) | (44.19K) | [{"date":"2019-09-30","value":100,"profit":true},{"date":"2020-09-30","value":-6.82,"profit":false},{"date":"2021-09-30","value":-3.23,"profit":false},{"date":"2022-09-30","value":-2.52,"profit":false},{"date":"2023-09-30","value":-0.54,"profit":false}] |
Gross Margin | 99.71% | (9.47%) | - | - | - | [{"date":"2019-09-30","value":100,"profit":true},{"date":"2020-09-30","value":-9.49,"profit":false},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true}] |
Operating Expenses | 29.33M | 36.31M | 51.73M | 63.07M | 53.13M | [{"date":"2019-09-30","value":46.5,"profit":true},{"date":"2020-09-30","value":57.58,"profit":true},{"date":"2021-09-30","value":82.01,"profit":true},{"date":"2022-09-30","value":100,"profit":true},{"date":"2023-09-30","value":84.23,"profit":true}] |
Operating Income | (36.30M) | (36.84M) | (51.73M) | (63.07M) | (53.13M) | [{"date":"2019-09-30","value":-3629906100,"profit":false},{"date":"2020-09-30","value":-3684100000,"profit":false},{"date":"2021-09-30","value":-5172700000,"profit":false},{"date":"2022-09-30","value":-6307075300,"profit":false},{"date":"2023-09-30","value":-5312638200,"profit":false}] |
Total Non-Operating Income/Expense | (5.10M) | (3.43M) | (2.37M) | (4.47M) | (7.41M) | [{"date":"2019-09-30","value":-510241500,"profit":false},{"date":"2020-09-30","value":-342729400,"profit":false},{"date":"2021-09-30","value":-237074000,"profit":false},{"date":"2022-09-30","value":-446616700,"profit":false},{"date":"2023-09-30","value":-741348600,"profit":false}] |
Pre-Tax Income | (37.93M) | (38.51M) | (53.16M) | (66.05M) | (58.98M) | [{"date":"2019-09-30","value":-3793478800,"profit":false},{"date":"2020-09-30","value":-3851100000,"profit":false},{"date":"2021-09-30","value":-5316100000,"profit":false},{"date":"2022-09-30","value":-6604946400,"profit":false},{"date":"2023-09-30","value":-5897986800,"profit":false}] |
Income Taxes | (3.41M) | (3.27M) | 2.00K | 2.80K | 2.80K | [{"date":"2019-09-30","value":-121821.46,"profit":false},{"date":"2020-09-30","value":-116857.14,"profit":false},{"date":"2021-09-30","value":71.43,"profit":true},{"date":"2022-09-30","value":100,"profit":true},{"date":"2023-09-30","value":100,"profit":true}] |
Income After Taxes | (34.52M) | (35.24M) | (53.16M) | (66.05M) | (58.98M) | [{"date":"2019-09-30","value":-3452378700,"profit":false},{"date":"2020-09-30","value":-3523900000,"profit":false},{"date":"2021-09-30","value":-5316300000,"profit":false},{"date":"2022-09-30","value":-6605226400,"profit":false},{"date":"2023-09-30","value":-5898266800,"profit":false}] |
Income From Continuous Operations | (34.52M) | (35.24M) | (53.16M) | (66.05M) | (58.98M) | [{"date":"2019-09-30","value":-3452378700,"profit":false},{"date":"2020-09-30","value":-3523949800,"profit":false},{"date":"2021-09-30","value":-5316334800,"profit":false},{"date":"2022-09-30","value":-6605226400,"profit":false},{"date":"2023-09-30","value":-5898300000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-09-30","value":"-","profit":true},{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true}] |
Net Income | (34.52M) | (35.24M) | (53.16M) | (66.05M) | (58.98M) | [{"date":"2019-09-30","value":-3452378700,"profit":false},{"date":"2020-09-30","value":-3523900000,"profit":false},{"date":"2021-09-30","value":-5316300000,"profit":false},{"date":"2022-09-30","value":-6605226400,"profit":false},{"date":"2023-09-30","value":-5898266800,"profit":false}] |
EPS (Diluted) | (1.66) | (0.65) | (0.37) | (0.31) | (0.24) | [{"date":"2019-09-30","value":-166,"profit":false},{"date":"2020-09-30","value":-65,"profit":false},{"date":"2021-09-30","value":-37,"profit":false},{"date":"2022-09-30","value":-31,"profit":false},{"date":"2023-09-30","value":-24,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
OTLK | |
---|---|
Cash Ratio | 0.75 |
Current Ratio | 1.07 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
OTLK | |
---|---|
ROA (LTM) | -83.69% |
ROE (LTM) | -3.65% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
OTLK | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 2.78 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -1.78 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
OTLK | |
---|---|
Trailing PE | NM |
Forward PE | 2.85 |
P/S (TTM) | 13.27 |
P/B | 10.19 |
Price/FCF | NM |
EV/R | 26.10 |
EV/Ebitda | NM |
OUTLOOK THERAPEUTICS INC (OTLK) share price today is $1.495
Yes, Indians can buy shares of OUTLOOK THERAPEUTICS INC (OTLK) on Vested. To buy OUTLOOK THERAPEUTICS INC from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in OTLK stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of OUTLOOK THERAPEUTICS INC (OTLK) via the Vested app. You can start investing in OUTLOOK THERAPEUTICS INC (OTLK) with a minimum investment of $1.
You can invest in shares of OUTLOOK THERAPEUTICS INC (OTLK) via Vested in three simple steps:
The 52-week high price of OUTLOOK THERAPEUTICS INC (OTLK) is $12.85. The 52-week low price of OUTLOOK THERAPEUTICS INC (OTLK) is $0.87.
The price-to-earnings (P/E) ratio of OUTLOOK THERAPEUTICS INC (OTLK) is
The price-to-book (P/B) ratio of OUTLOOK THERAPEUTICS INC (OTLK) is 10.19
The dividend yield of OUTLOOK THERAPEUTICS INC (OTLK) is 0.00%
The market capitalization of OUTLOOK THERAPEUTICS INC (OTLK) is $33.83M
The stock symbol (or ticker) of OUTLOOK THERAPEUTICS INC is OTLK